Poseida Therapeutics Announces FDA Clearance Of Investigational New Drug Application For P-CD19CD20-ALLO1, An Allogeneic Dual CAR-T Cell Therapy For B-Cell Malignancies
Portfolio Pulse from Happy Mohamed
Poseida Therapeutics, Inc. (NASDAQ:PSTX) has received FDA clearance for its Investigational New Drug (IND) application for P-CD19CD20-ALLO1, a dual CAR-T cell therapy for B-cell malignancies. This is the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20. The therapy is being developed in partnership with Roche and will be evaluated in a Phase 1 study involving up to 70 adult patients.
July 05, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics has received FDA clearance for its IND application for P-CD19CD20-ALLO1, a dual CAR-T cell therapy for B-cell malignancies. This positive regulatory milestone could potentially boost investor confidence and the company's stock in the short term.
FDA clearance for an IND application is a significant regulatory milestone for a biotech company like Poseida Therapeutics. This clearance allows the company to proceed with clinical trials, which if successful, could lead to commercialization of the therapy. This news could potentially boost investor confidence in the company's research and development capabilities, and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100